Comparison of the Efficacy of Carbetocin and Oxytocin in Preventing Postpartum Hemorrhage in Preeclampsia Patients at Samutprakarn Hospital
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To compare the efficacy of Carbetocin and Oxytocin in preventing postpartum hemorrhage in preeclamptic women.
METHODS: This retrospective study included 520 preeclamptic women who received either Carbetocin or Oxytocin for the prevention of PPH at Samut Prakan Hospital between January 1, 2020, and July 31, 2024. The participants were randomly divided into two groups: the Carbetocin group (n=260) received 100 mcg of Carbetocin diluted in 100 ml of 0.9% normal saline intravenously, and the Oxytocin group (n=260) received 10-20 IU of Oxytocin diluted in 100 ml of 0.9% normal saline intravenously. Maternal clinical outcomes and blood loss were analyzed statistically between the two groups.
RESULTS: Estimated blood loss 1,000 mL was observed in 2 patients (0.8%) in the Carbetocin group and 4 patients (1.5%) in the Oxytocin group, with no statistically significant difference (p=0.686). Patients in the Carbetocin group had significantly higher SBP and DBP at admission and before drug administration (p-value < 0.01) than the Oxytocin group, but no significant difference was noted after drug administration. No significant differences in maternal outcomes were found between the two groups.
CONCLUSIONS: Carbetocin and Oxytocin demonstrate comparable efficacy in preventing postpartum hemorrhage, with no statistically significant impact on maternal hemodynamic stability or outcomes. Therefore, drug selection should consider cost-effectiveness, drug availability, and healthcare resource constraints. Encouraging patient involvement in treatment decisions grounded in evidence-based medicine and health economics—can facilitate shared decision-making between healthcare providers and patients. This approach is particularly relevant in healthcare systems that strive to balance high-quality care with efficient resource utilization.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Magee LA, Nicolaides KH, Dadelszen P von. Preeclampsia. N Engl J Med. 2022 May 11;386(19):1817–32.
แนวทางเวชปฏิบัติของราชวิทยาลัยสููตินรีแพทย์แห่งประเทศไทย-rtcog-clinical-practice-guideline- [Internet]. [cited 2024 Aug 11]. Available from: https://www.rtcog.or.th/content/viewid/276
Nyfløt LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Risk factors for severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth. 2017 Jan 10;17:17.
Al Anwar AM, Abdal Salam HS, Esukni SM, Abdel Rahman MM. Carbetocin versus Oxytocin: A Comparative Study to Prevent Postpartum Hemorrhage in Pre-eclamptic Women Delivered by Caesarean Section. Egypt J Hosp Med. 2022 Oct 1;89(1):5063–8.
Giouleka S, Tsakiridis I, Kalogiannidis I, Mamopoulos A, Tentas I, Athanasiadis A, et al. Postpartum Hemorrhage: A Comprehensive Review of Guidelines. Obstet Gynecol Surv. 2022 Nov;77(11):665–82.
Alliance for Maternal and Newborn Health Improvement (AMANHI) mortality study group. Population-based rates, timing, and causes of maternal deaths, stillbirths, and neonatal deaths in south Asia and sub-Saharan Africa: a multi-country prospective cohort study. Lancet Glob Health. 2018 Dec;6(12):e1297–308.
Leduc D, Senikas V, Lalonde AB. No. 235-Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2018 Dec;40(12):e841–55.
Heneghan C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet Lond Engl. 2012 Jan 28;379(9813):322–34.
Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2013 Oct 30;(10):CD001808.
Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gülmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG Int J Obstet Gynaecol. 2016 Dec;123(13):2076–86.
Malm M, Madsen I, Kjellström J. Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries. J Pept Sci. 2018 Jun;24(6):e3082.
Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis. Medicine (Baltimore). 2019 Nov;98(47):e17911.
Reyes OA, Gonzalez GM. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with severe preeclampsia: a double-blind randomized controlled trial. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2011 Nov;33(11):1099–104.
Caceda SI, Ramos RR, Saborido CM. Pharmacoeconomic study comparing carbetocin with oxytocin for the prevention of hemorrhage following cesarean delivery in Lima, Peru. J Comp Eff Res. 2018 Jan;7(1):49–55.
Matthijsse S, Andersson FL, Gargano M, Yip Sonderegger YL. Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom. J Med Econ. 2022;25(1):129–37.
Gil-Rojas Y, Lasalvia P, Hernández F, Castañeda-Cardona C, Rosselli D. Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia. Rev Bras Ginecol E Obstet Rev Fed Bras Soc Ginecol E Obstet. 2018 May;40(5):242–50.
You JHS, Leung TY. Cost-effectiveness analysis of carbetocin for prevention of postpartum hemorrhage in a low-burden high-resource city of China. PloS One. 2022;17(12):e0279130.
Maged AM, Hassan AMA, Shehata NAA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2016;29(4):532–6.
Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun 1;2(6):e323–33.
Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992 Jul;52(1):60–7.
Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, Leetheeragul J, Sirisomboon R, Jiraprasertwong R. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial. Arch Gynecol Obstet. 2018 Aug;298(2):319–27.
Pisani I, Tiralongo GM, Gagliardi G, Scala RL, Todde C, Frigo MG, et al. The maternal cardiovascular effect of carbetocin compared to oxytocin in women undergoing caesarean section. Pregnancy Hypertens Int J Womens Cardiovasc Health. 2012 Apr 1;2(2):139–42.
